PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex

Tuberous sclerosis complex (TSC) is caused by inactivating mutations in either TSC1 or TSC2 and is characterized by uncontrolled mTORC1 activation. Drugs that reduce mTOR activity are only partially successful in the treatment of TSC, suggesting that mTOR-independent pathways play a role in disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Maria M., Fuhler, Gwenny M., Queiroz, Karla C.S., Scholma, Jetse, Goorden, Susan, Anink, Jasper, Arnold Spek, C., Hoogeveen-Westerveld, Marianne, Bruno, Marco J., Nellist, Mark, Elgersma, Ype, Aronica, Eleonora, Peppelenbosch, Maikel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585940/
https://www.ncbi.nlm.nih.gov/pubmed/26412398
http://dx.doi.org/10.1038/srep14534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585940/
https://www.ncbi.nlm.nih.gov/pubmed/26412398
http://dx.doi.org/10.1038/srep14534

Ejemplares similares